AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22123796
Drug: Nicotine therapy
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine therapy sampling
Trial: 19619700
Drug: Baseline use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline use of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB)
Trial: 11128341
Drug: Lisinopril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10-20 mg once a day)
Trial: 11128341
Drug: Nisoldipine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (20-40 mg once a day)
Trial: 30345611
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of ranibizumab + pro re nata (prn)
Trial: 30345611
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of ranibizumab + pro re nata (prn)
Trial: 28691269
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/hour infusion)
Trial: 28691269
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (same bolus and infusion rate as lidocaine)
Trial: 27317550
Drug: Ametop™ (tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ametop™ (tetracaine 4%) gel applied to the skin of the lower back at least 20min before neuraxial block
Trial: 21971356
Drug: High-titer neutralizing
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-titer neutralizing antibodies (NAb) against two or more isolates (90% inhibitory dose > 500)
Trial: 19857447
Drug: 3 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 μg IXIARO®
Trial: 19857447
Drug: 6 μg
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 μg IXIARO®
Trial: 15095213
Drug: Azithromycin, 500
RxNorm normalized name: Azithromycin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 500 mg per week for 8 weeks (R1)
Trial: 15095213
Drug: Azithromycin, 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 1500 mg once at enrollment (R2)
Trial: 15095213
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (R3)
Trial: 11806304
Drug: H1 antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 antihistamines
Trial: 9551842
Drug: Tiagabine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (10 mg three-times daily)
Trial: 3051945
Drug: CG-120 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG-120 (3 or 4 g daily)
Trial: 31588557
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of endocrine therapy
Trial: 31588557
Drug: Residing in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residing in a higher income area; having progesterone receptor-positive tumors; receipt of chemotherapy, radiotherapy, and endocrine therapy
Trial: 30945623
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg olanzapine (arm A; n=27)
Trial: 30945623
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg olanzapine plus 4 mg dexamethasone (arm B; n=27)
Trial: 30945623
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone (reference arm C; n=27)
Trial: 21631509
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy (oral hygiene instructions and subgingival scaling and root planing)
Trial: 16476678
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel (n = 24) for 15 days before FSH treatment
Trial: 16476678
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (n = 25) for 15 days before FSH treatment
Trial: 8321836
Drug: Felodipine extended-release
RxNorm normalized name: Felodipine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine extended-release (ER) tablets 10 mg under fasting conditions
Trial: 8321836
Drug: Felodipine extended-release
RxNorm normalized name: Felodipine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine extended-release (ER) tablets 10 mg under nonfasting conditions
Trial: 8321836
Drug: Felodipine extended-release
RxNorm normalized name: Felodipine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine extended-release (ER) tablets 10 mg
Trial: 8321836
Drug: Felodipine extended-release
RxNorm normalized name: Felodipine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine extended-release (ER) tablets 10 mg with food
Trial: 3963319
Drug: Oral physiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral physiological NaCl solution
Trial: 3963319
Drug: Intramuscular physiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular physiological NaCl solution
Trial: 3963319
Drug: Parenteral premedication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral premedication
Trial: 22519922
Drug: Bavisant 1
RxNorm normalized name: Bavisant
DrugBank: Bavisant (DB12299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bavisant 1 mg/day
Trial: 22519922
Drug: Bavisant 3
RxNorm normalized name: Bavisant
DrugBank: Bavisant (DB12299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bavisant 3 mg/day
Trial: 22519922
Drug: Bavisant 10
RxNorm normalized name: Bavisant
DrugBank: Bavisant (DB12299)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bavisant 10 mg/day
Trial: 22519922
Drug: OROS Methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS Methylphenidate 54 mg/day
Trial: 20511610
Drug: subcutaneous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subcutaneous methotrexate (scMTX)
Trial: 20511610
Drug: ciclosporin added
RxNorm normalized name: ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ciclosporin added to oral methotrexate (MTX)
Trial: 12889354
Drug: Leflunomide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (20 mg/daily)
Trial: 12889354
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of leflunomide and methotrexate
Trial: 12889354
Drug: Detralex in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detralex in combination with methotrexate
Trial: 1873003
Drug: 4 to
RxNorm normalized name: LMX 4 Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 to 8 mg perindopril given once daily
Trial: 1873003
Drug: 25 to
RxNorm normalized name: Hydrasyn25 Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 to 50 mg captopril given twice daily
Trial: 29908708
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical parameters (age, pulmonary rales, systolic blood pressure, cause of heart failure, osteoporosis, current smoking, NT‐proBNP, haemoglobin, QRS width, heart rhythm)
Trial: 22614228
Drug: Quercetin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (1,000 mg·d⁻¹ for 8.5 days)
Trial: 20233179
Drug: Oral clotrimazole
RxNorm normalized name: clotrimazole Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral clotrimazole troches 10 mg taken three times daily for 5 days
Trial: 20233179
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 2 mg or intravenous midazolam 0.025 mg kg(‐1) without clotrimazole
Trial: 10594437
Drug: Intubating laryngeal
RxNorm normalized name: LARYNGEAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intubating laryngeal mask using a fibreoptic bronchoscope (group L)
Trial: 8210718
Drug: ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketotifen 1 mg b.i.d.
Trial: 3534848
Drug: Capozide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capozide (50 mg captopril and 25 mg hydrochlorothiazide)
Trial: 28039477
Drug: New risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New risk assessment model for PSA 4-10 ng/mL
Trial: 28039477
Drug: New risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New risk assessment model for PSA 10-50 ng/mL
Trial: 28039477
Drug: PSA alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA alone for PSA 4-10 ng/mL
Trial: 28039477
Drug: PSA alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA alone for PSA 10-50 ng/mL
Trial: 19456296
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitor use
Trial: 20299114
Drug: Nonuse of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonuse of glycoprotein IIb/IIIa inhibitor
Trial: 2939239
Drug: Latamoxef (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latamoxef (1 g intravenous injection at induction of anaesthesia)
Trial: 31733781
Drug: Multimodal approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal approach including patient education, manual therapy, therapeutic exercise programs, and orthotic provision
Trial: 22776534
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT, 16 sessions)
Trial: 22776534
Drug: Duloxetine (30-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (30-60 mg/d)
Trial: 22776534
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT and antidepressant medication (for non-remitters)
Trial: 15054512
Drug: Cariporide 20
RxNorm normalized name: Cariporide
DrugBank: Cariporide (DB06468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariporide 20 mg
Trial: 15054512
Drug: Cariporide 80
RxNorm normalized name: Cariporide
DrugBank: Cariporide (DB06468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariporide 80 mg
Trial: 11850979
Drug: Adrenocorticotropic hormone
RxNorm normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenocorticotropic hormone stimulation test
Trial: 7949544
Drug: SP of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP of PBMC in patients treated with anti‐interleukin‐2‐receptor antibody, BT563 (n=8)
Trial: 2884410
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) at doses of 10 to 800 micrograms
Trial: 2884410
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) at 800 micrograms
Trial: 2884410
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA Plasmodium falciparum sporozoite vaccine (FSV‐1) with a fourth dose
Trial: 29098908
Drug: Desoximetasone 0.05%
RxNorm normalized name: DESOXIMETASONE 0.05% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desoximetasone 0.05% topical spray
Trial: 29098900
Drug: Vehicle topical
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle topical spray
Trial: 22889095
Drug: AgNano 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AgNano 10 mg/kg
Trial: 22889095
Drug: AgNano 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AgNano 20 mg/kg
Trial: 22889095
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg/kg AgNano)
Trial: 20214066
Drug: Flour capsule
RxNorm normalized name: Flours
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flour capsule (Placebo)
Trial: 12067837
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus lipid/heparin infusion
Trial: 1898641
Drug: Recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) therapy
Trial: 27930497
Drug: VPA +
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA + DM (30 mg/d)
Trial: 27930497
Drug: VPA +
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA + DM (60 mg/d)
Trial: 26869049
Drug: Nab-paclitaxel 150
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel 150 mg/m² (reduced to 125 mg/m² after 464 participants)
Trial: 26869049
Drug: Solvent-based paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solvent-based paclitaxel 80 mg/m²
Trial: 25389139
Drug: Nebulised 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised 3% hypertonic saline (HS) administered 6-hourly
Trial: 19486466
Drug: Topical fluoride
RxNorm normalized name: Carles 60 Second APF 1.23% Topical Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoride varnish three times per school year
Trial: 19486466
Drug: Varnish plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varnish plus twice‐per‐day toothbrushing and xylitol containing gummy bear snacks
Trial: 10770301
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (dalteparin 100 IU/kg subcutaneously twice a day)
Trial: 10770301
Drug: Aspirin (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (160 mg every day)
Trial: 8447210
Drug: P6 acupoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P6 acupoint injection with 0.2 ml 50% glucose in water
Trial: 8447210
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 20 micrograms/kg droperidol
Trial: 30946442
Drug: Ibuprofen, 10
RxNorm normalized name: Ibuprofen, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen, 10 mg/kg every 6 hours for the first 9 postoperative days
Trial: 30946442
Drug: Acetaminophen, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen, 15 mg/kg every 6 hours for the first 9 postoperative days
Trial: 28138803
Drug: Liraglutide treatment
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide treatment in primary care (PCP)
Trial: 28138803
Drug: Liraglutide treatment
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide treatment in specialist care
Trial: 28138803
Drug: Liraglutide treatment
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide treatment in PCP
Trial: 23187164
Drug: Topical bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Topical bevacizumab (5 mg/mL) 4 times daily for 2 months
Trial: 23187164
Drug: Artificial tear
RxNorm normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial tear 4 times daily for 2 months
Trial: 16546766
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (average of 11 individual sessions over 20 weeks)
Trial: 12836580
Drug: Attachment-based family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-based family therapy (ABFT); specific treatment strategies targeting relational ruptures and rebuilding relationships; details on dosage and duration not available.
Trial: 10679658
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy alone (Arm A)
Trial: 10679658
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (Arm B)
Trial: 2430797
Drug: Hyperbaric 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric 0.5% bupivacaine (2.5 ml in 8% dextrose)
Trial: 2430797
Drug: Hyperbaric 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric 0.5% cinchocaine (1.5 ml in 6% dextrose)
Trial: 23507136
Drug: Interviewer-administered Clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interviewer-administered Clinical Interview Schedule (CIS-R)
Trial: 18287591
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (0.05 mg/kg)
Trial: 14583341
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g daily of purified eicosapentaenoic acid (EPA) for 6 weeks
Trial: 14583341
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g daily of docosahexaenoic acid (DHA) for 6 weeks
Trial: 11177158
Drug: 100 IU/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 IU/d of recombinant follicle‐stimulating hormone
Trial: 11177158
Drug: 200 IU/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU/d of recombinant follicle‐stimulating hormone
Trial: 9226493
Drug: Palatable meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palatable meal (Ensure, 1048 KJ, 450 ml)
Trial: 25572450
Drug: Selegiline transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline transdermal system
Trial: 20048683
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g rPC daily
Trial: 20048683
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g rPC daily
Trial: 20048683
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g rPC daily
Trial: 20048683
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g rPC daily
Trial: 14562520
Drug: Interpretive short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interpretive short-term group therapy
Trial: 14562520
Drug: Supportive short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supportive short-term group therapy
Trial: 1839644
Drug: Oral CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CBD (10 mg/kg/day for 6 weeks)
Trial: 6623221
Drug: Enflurane as
RxNorm normalized name: Enflurane
DrugBank: Enflurane (DB00228)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enflurane as a volatile supplement to nitrous oxide anesthesia
Trial: 6623221
Drug: Halothane as
RxNorm normalized name: Halothane
DrugBank: Halothane (DB01159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Halothane as a volatile supplement to nitrous oxide anesthesia
Trial: 23473527
Drug: Exenatide 5
RxNorm normalized name: EXENATIDE 5MCG/DOSE 1.2ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 5 μg BID for 4 weeks, then 10 μg BID for 12 weeks
Trial: 22611676
Drug: Mexidol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexidol (100 mg intramuscular for 10 days, then 125 mg orally three times a day for 20 days)
Trial: 22611676
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment (Diroton 5-20 mg daily, Cardiomagnyl 75 mg daily)
Trial: 19256262
Drug: Creon (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creon (25 or 50% higher dose)
Trial: 15094530
Drug: Individualized physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized physical therapy without specific stabilizing exercises
Trial: 10214426
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (treatment group)
Trial: 2155958
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (2 mg, two puffs, four times per day for 12 weeks)
Trial: 7428402
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg vincamine
Trial: 31862004
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 50 mg/kg loading dose and 30 mg/kg/h continuous maintenance infusion for 1 h (group H)